

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ANCLIFF, Rachael *et al.* Confirmation No.: 5647
Serial No.: 10/531,758 Group Art Unit: 1624
Filing Date: April 14, 2005 Examiner: COLEMAN, Brenda Libby
Title: *Substituted Piperazines (1,4) Diazepines, and 2,5-Diazabicyclo (2.2.1) Heptanes as Histamine H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists*

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY AND AMENDMENT UNDER 37 CFR §1.111

Sir:

The following is in reply to the non-final Office Action dated December 15, 2008. It is filed with a one-month extension of time, bringing the period of response to on or before April 15, 2009.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR §1.16 or §1.17, and any necessary extension of time fees, to Deposit Account No. 07-1392.

Amendments to the Specification begin on page 2.

Amendments to the Claims are reflected in the listing of claims which begins on page 3.

Remarks begin on page 7.

Please amend the application as follows: